Safety and Performance of a Hernia Blocking System

Inclusion Criteria: * Subject is between 18 and 75 years of age. * Posterolateral disc herniation at one level between L4 and S1 with radiographic confirmation (CT and/or MRI) of neural compression. * At least six weeks of failed conservative treatment prior to surgery, including physical therapy, use of anti-inflammatory medications at maximum specified dosage and/or administration of epidural/facet injections. * Minimum posterior disc height of 5 mm at the index level. * Radiculopathy with positive straight leg raise test. * ODI score of at least 40/100. * Subjects who are able to give voluntary informed consent to participate in the clinical investigation and from whom consent has been obtained. * Subject is able and willing to comply with the protocol requirements. Exclusion Criteria: * Spondylolisthesis and/or instability at the index level. * Foraminal, extra-foraminal or central disc herniation. * Subject has clinically compromised vertebral bodies in the lumbosacral region due to any traumatic, neoplastic, metabolic, or infectious pathology. * Subject has scoliosis of greater than 20 degrees (both angular and rotational). * Less than 20 mm of interpedicular distance in the spinal canal at the index level. * Grossly distorted anatomy due to congenital abnormalities. * Deformation that affect the posterior corners of the vertebra at the index level (e.g., osteophytes). * Endplate irregularities that, in the judgment of the surgeon, could affect the device implantation. * Prior surgery at the index lumbar vertebral level. * Radiological confirmation of severe facet joint disease or degeneration. * Patients diagnosed or at a high risk of osteoporosis (such as postmenopausal women and patients receiving long-term treatment with corticosteroids) who present a bone densitometry DXA T-score of less than -2.0 at the index level. * Cauda equina syndrome. * Fever, leucocytosis and/or systemic or localized active infection. * Systemic inflammation and/or inflammation at the implantation site. * Any metabolic bone disease. * Insulin-dependent diabetes mellitus. * Peripheral neuropathy. * Active hepatitis, AIDS or HIV. * Rheumatoid arthritis or other autoimmune disease. * Active or history of any invasive malignancy; patients with curatively-treated malignancies who have been disease-free for at least 5 years are eligible. * Active tuberculosis or history of tuberculosis in the past 3 years. * Immunologically suppressed patients. * Current anticoagulation therapy, unless anticoagulation therapy can be suspended for surgery. * Patients who have received medication (e.g., methotrexate, alendronate) that interferes with bone mineral metabolism within 4 weeks of the planned date of the index surgery. * Suspected or known allergies or intolerance to the implant materials. * Any condition that precludes the use of general anesthesia. * Any condition that precludes the surgical procedure. * Any contraindication for MRI or CT scan. * Class III obesity: Body mass index ≥ 40. * Current alcohol or recreational drug dependency. * Pregnant or interested in becoming pregnant in the following 24 months. * Breastfeeding. * Life expectancy less than 2 years. * Subject is currently participating or has participated in the previous 4 weeks in any other interventional clinical study.